Table 2.
Number, type of cycles of CHT, number of NECe, and median length of days of neutropenia grade IV in AML patients during the study period (2007-2023).
| Therapy | Total number of cycles delivered (n) | Median length neutropenia grade IV (range) | NECe number | NECe/Total (%) |
|---|---|---|---|---|
| 5 + 2 (ida) | 66 | 5 (2-13) | 0 | 0 |
| 5 + 3+3 (cyta-ida-eto) | 110 | 7 (1-22) | 6 | 5.4 |
| 7 + 3 (dauno) | 40 | 14 (6-22) | 10 | 25 |
| 7 + 3 (ida) | 120 | 13 (8-22) | 17 | 14.2 |
| AML 1310 (ind) | 17 | 14 (5-24) | 8 | 47 |
| AML 1310 (cons) | 11 | 7 (5-14) | 1 | 9.1 |
| HD ARA-C | 64 | 2 (0-6) | 0 | 0 |
| CPX-351 (ind1) | 22 | 19.5 (12-24) | 0 | 0 |
| CPX-351 (ind2) | 1 | 9 (NA) | 0 | 0 |
| CPX-351 (cons) | 14 | 11 (6-22) | 0 | 0 |
| Tot | 465 | 42 | 9.0 |
5 + 2 (ida)= idarubicin 13 mg/m2/d for 2 days, and cytarabine 100 mg/m2/d as a continuous for 5 days (50)); 5 + 3 + 3 (cyta-ida-eto); cytosine arabinoside (100 mg/m2, six doses), idarubicin (8 mg/m2, three doses), and etoposide (100 mg/m2, five doses) (51); 7 + 3 = 7-day continuous infusion of cytarabine at the dosage of 200 mg/m2 per day on days 1 to 7 and daunorubicin at 60 mg/m2 per day on days 1 to 3 (52); 7 + 3 ida = idarubicin 12 mg/m2 for 3 days and cytarabine was given in a dose of 100 mg/m2 continuous IV infusion for 7 days (53); GIMEMA AML1310 (ind)= induction consisted of IV daunorubicin 50 mg/m2 daily on days 1, 3, and 5; IV etoposide 50 mg/m2 daily on days 1 to 5; and IV cytarabine 100 mg/m2 as a daily continuous infusion, days 1 to 10 (54); GIMEMA AML1310 (cons) = IV daunorubicin 50 mg/m2 daily on days 4, 5, and 6 and IV cytarabine 500 mg/m2 every 12 hours on days 1 to 6 (54); HD ARA-C: consolidation with high dose cytarabine 3g/m2 every 12 h on days 1,3,5 (55, 56). CPX-351 ind1: CPX-351 100 units per m² (daunorubicin 44 mg/m² plus cytarabine 100 mg/m²) as a 90-min infusion on days 1, 3, and 5 (57); CPX-351 ind2: CPX-351 100 units per m² (daunorubicin 44 mg/m² plus cytarabine 100 mg/m²) as a 90-min infusion on days 1, 3 (57); CPX-351 cons: 65 units per m² (daunorubicin 29 mg/m² plus cytarabine 65 mg/m²) administered as a 90-min infusion on days 1 and 3 (57).